Trial · NCT04572243
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Core Study: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Treatment Period | Core Study: Placebo | 18.78 | Full Range -53.7 to 131.5 | percent change | |
| Core Study: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Treatment Period | Core Study: Lorcaserin | -78.88 | Full Range -100.0 to 542.9 | percent change | |
| Core Study: Percentage of Participants With 50% or Greater Response for Convulsive Seizures in the Treatment Period Compared to Baseline | Core Study: Placebo | 20.0 | percentage of participants | ||
| Core Study: Percentage of Participants With 50% or Greater Response for Convulsive Seizures in the Treatment Period Compared to Baseline | Core Study: Lorcaserin | 60.0 | percentage of participants | ||
| Core Study: Percentage of Participants Who Were Free From Convulsive Seizures in the Treatment Period | Core Study: Placebo | 0.0 | percentage of participants | ||
| Core Study: Percentage of Participants Who Were Free From Convulsive Seizures in the Treatment Period | Core Study: Lorcaserin | 10.0 | percentage of participants | ||
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 1: Pre-dose | 52.0 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 1: 1 to 2 hours post-dose | 106 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 2: Pre-dose | 22.1 | Standard Deviation 14.5 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 2: 1 to 2 hours post-dose | 32.7 | Standard Deviation 22.7 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 4: Pre-dose | 48.5 | Standard Deviation 13.2 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 4: 1 to 2 hours post-dose | 107 | Standard Deviation 76.9 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 4: 3 to 6 hours post-dose | 60.5 | Standard Deviation 36.0 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 6: Pre-dose | 22.7 | Standard Deviation 11.8 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 6: 1 to 2 hours post-dose | 41.0 | Standard Deviation 20.6 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 10: Pre-dose | 32.9 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 10: 1 to 2 hours post-dose | 52.4 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 10: 3 to 6 hours post-dose | 66.7 | Standard Deviation 33.7 | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 15: Pre-dose | 33.6 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
| Core Study: Plasma Concentrations of Lorcaserin | Core Study: Lorcaserin | Week 15: 1 to 2 hours post-dose | 31.4 | Standard Deviation NA | nanograms per milliliter (ng/mL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04572243/results